Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $21.20 USD
Change Today +1.16 / 5.79%
Volume 722.0K
INSM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

insmed inc (INSM) Snapshot

Open
$20.25
Previous Close
$20.04
Day High
$21.24
Day Low
$20.00
52 Week High
04/24/15 - $24.00
52 Week Low
08/12/14 - $11.25
Market Cap
1.3B
Average Volume 10 Days
688.8K
EPS TTM
$-1.85
Shares Outstanding
61.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INSMED INC (INSM)

insmed inc (INSM) Related Bloomberg News

View More Bloomberg News

insmed inc (INSM) Related Businessweek News

No Related Businessweek News Found

insmed inc (INSM) Details

Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing inhaled therapies for patients with serious lung diseases. Its lead product candidate is ARIKAYCE, an inhaled antibiotic treatment that delivers an anti-infective directly to the site of serious lung infections. The company’s ARIKAYCE is in Phase III clinical trial for patients with lung infections caused by non-tuberculous mycobacteria (NTM) in the United States and Canada; and completed a Phase III clinical trial in Europe and Canada for cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. It also focuses on the development of INS1009, an inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension. Insmed Incorporated was founded in 1999 and is headquartered in Bridgewater, New Jersey.

89 Employees
Last Reported Date: 02/27/15
Founded in 1999

insmed inc (INSM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $465.0K
Chief Financial Officer
Total Annual Compensation: $340.8K
General Counsel and Corporate Secretary
Total Annual Compensation: $354.7K
Senior Vice President of Human Resources & Co...
Total Annual Compensation: $303.8K
Vice President of Regulatory Affairs
Total Annual Compensation: $310.6K
Compensation as of Fiscal Year 2014.

insmed inc (INSM) Key Developments

Insmed Incorporated Seeks Acquisitions

Insmed Incorporated (NasdaqGS:INSM) is expects to raise approximately $194 million through sale of common stock. Insmed will use the proceeds to fund working capital, potential debt repayment, capital expenditures, general research and development, and other general corporate purposes, which may include the acquisition or in-license of additional compounds, product candidates, technology or businesses.

Insmed Incorporated Mulls Acquisitions

Insmed Incorporated (NasdaqGS:INSM) is seeking acquisitions. Insmed Incorporated announced commencement of underwritten public offering of 10.0 million shares of its common stock and intend to use the proceed from the offering for general corporate purposes, which may include the acquisition or in-license of additional compounds, product candidates, technology or businesses.

Eugene Sullivan Joins Insmed Incorporated as Chief Medical and Scientific Officer

Insmed Incorporated announced that Eugene Sullivan, M.D. has joined the company as its Chief Medical and Scientific Officer. Dr. Sullivan will report to Will Lewis, President and Chief Executive Officer. In recent years, Dr. Sullivan was a Vice President, Global Regulatory Affairs at Astra Zeneca and consulted to companies, including Insmed, on clinical drug development and strategic regulatory matters.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSM:US $21.20 USD +1.16

INSM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INSM.
View Industry Companies
 

Industry Analysis

INSM

Industry Average

Valuation INSM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSMED INC, please visit www.insmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.